The 20th Annual Scientific Conference and Exposition of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas (NAPPSA), recently concluded at the Hyatt Regency Aurora-Denver Conference Centre in Colorado, has served as a critical platform for addressing the systemic paralysis currently stifling Nigeria’s pharmaceutical and healthcare sectors. Pharm. (Dr.) Adekunle Tometi, President of the association, used the international stage to issue a stern directive to Nigerian policymakers: the nation’s reliance on imported healthcare solutions is no longer sustainable, and the path to sovereignty lies in dismantling the regulatory and infrastructural bottlenecks that prevent local scientific brilliance from reaching the patient.
The event, which drew experts from across the globe, focused on the theme "Globalising Innovations in Healthcare: Bridging Science, Access and Impact." The discourse underscored a stark reality: while Nigeria possesses an abundance of intellectual capital and academic talent, it suffers from a chronic inability to translate these assets into commercialized, life-saving products.
The Innovation Gap: From Discovery to Distribution
A central theme of the conference was the "translation deficit." Historically, Nigerian researchers have been prolific in generating discoveries within laboratory settings. However, these discoveries rarely progress beyond the prototype phase. The barriers identified by Dr. Tometi and his colleagues are multifaceted. Fragmented systems, unpredictable regulatory timelines, and a near-total lack of implementation science have created an environment where innovation is stifled at birth.
Data presented at the conference suggests that the current regulatory landscape is ill-equipped for the rapid pace of modern biotechnology. Approval timelines for new diagnostics and digital health tools remain sluggish, often frustrating innovators and driving investment capital toward more predictable markets. Furthermore, the absence of robust local manufacturing capacity—exacerbated by a reliance on the importation of active pharmaceutical ingredients (APIs)—renders Nigeria vulnerable to global supply chain shocks.
Chronology of Challenges and Policy Shifts
The evolution of Nigeria’s healthcare landscape over the last decade has been characterized by high aspiration but low execution. In 2017, the federal government signaled an intent to bolster local manufacturing through various executive orders, yet the impact has been negligible. By 2022, the lingering effects of the COVID-19 pandemic exposed the fragility of the nation’s supply chains, leading to a renewed call for "sovereign health security."
The 2026 NAPPSA conference marks a pivot point in this timeline. By inviting stakeholders from academia, the pharmaceutical industry, and technology sectors to one table, the association is attempting to force the integration of siloed entities. The strategy proposed by Dr. Tometi is not merely academic; it calls for the institutionalization of collaboration. Rather than relying on sporadic, voluntary partnerships, the NAPPSA president advocates for the creation of national innovation consortia. These bodies would be empowered to link university research departments directly with teaching hospitals and private sector manufacturers, effectively creating a "pipeline" for healthcare delivery.
Strengthening the Infrastructure for Scale
To move from the current state of dependency to a self-sustaining ecosystem, Nigeria requires a massive overhaul of its R&D funding architecture. Dr. Tometi noted that Nigeria currently invests less than 0.5 percent of its Gross Domestic Product (GDP) in research and development. To put this in perspective, the African Union has long recommended that member states target at least 1 percent, while innovation-driven economies like South Korea or Israel often exceed 4 percent.
The proposal to elevate this figure to 2 percent over the next five years is ambitious but necessary. Such funding, however, must be directed toward translational research—the process of turning lab findings into clinical tools—rather than purely theoretical academic studies. By offering tax incentives to pharmaceutical companies that invest in local R&D, the government could leverage private sector capital to bridge the current funding gap.
The Role of Diaspora Expertise
The Nigerian diaspora remains one of the country’s most underutilized assets. NAPPSA, acting as a bridge, has already begun facilitating mentorship programs and regulatory navigation assistance for startups in Nigeria. By utilizing the diaspora’s experience in navigating the regulatory hurdles of the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), local companies can align their quality control processes with international standards. This is a prerequisite for exporting Nigerian-made pharmaceutical products, which would not only boost the economy but also improve the global standing of Nigerian medical science.
Embracing the Digital Frontier with Guardrails
The rise of Artificial Intelligence (AI) and precision medicine presents both a massive opportunity and a significant risk. During the conference, experts highlighted that while digital health can bypass traditional infrastructural gaps—such as the lack of brick-and-mortar clinics in rural areas—it also introduces concerns regarding patient privacy and data sovereignty.
Dr. Tometi’s "responsible innovation" framework suggests that Nigeria must establish "regulatory sandboxes." These are controlled environments where developers can test new technologies under government supervision without the immediate burden of full-scale compliance, allowing for iteration while ensuring patient safety. Coupled with strong data protection laws, this approach could position Nigeria as a leader in African health technology.
Economic and Public Health Implications
The failure to scale local innovation has direct, quantifiable consequences on public health outcomes. Chronic diseases such as diabetes and hypertension, along with various forms of cancer, are increasingly burdening the Nigerian population. Without affordable access to the latest diagnostics and therapeutic innovations, mortality rates remain unnecessarily high.
From an economic standpoint, the current reliance on imports drains foreign exchange reserves. If Nigeria were to move toward a model of localized production—supported by the African Continental Free Trade Area (AfCFTA)—the country could capture a larger share of the continental pharmaceutical market. The shift to value-based reimbursement models, where therapies are paid for based on the clinical outcomes they produce rather than just the cost of the drug, could also incentivize the development of more effective, locally relevant treatments.
A Call for Execution
The discourse at the 20th NAPPSA conference concluded with a sobering reality: the roadmap for success is well-understood, but the execution remains lacking. The government, professional bodies, and the private sector are being urged to move beyond the language of "strategy sessions" and into the phase of tangible implementation.
For this to happen, the next twelve to twenty-four months are critical. Observers suggest that the government must move to establish the proposed multi-stakeholder review boards by the next fiscal year. Failure to do so risks further cementing Nigeria’s role as a perpetual consumer of global healthcare innovations rather than a participant in their creation.
As Dr. Tometi emphasized, the goal is to transform Nigerian pharmacists and scientists from passive recipients of imported technology into active architects of the global healthcare landscape. By integrating diaspora expertise, modernizing regulatory frameworks, and significantly increasing investment in the foundational elements of R&D, Nigeria possesses the potential to redefine its role in the global health ecosystem. The challenge now lies in the political will to treat healthcare innovation not as a luxury, but as a core pillar of national development.
